CoChat
Sign Up
Cited by 237Attention Deficit Hyperactivity DisorderHealth Systems, Economic Evaluations, Quality of LifeMental Health Treatment and Access

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Costs of attention deficit–hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000

Birnbaum, Howard G., Kessler, Ronald C., Lowe, Sarah W., Secnik, Kristina, Greenberg, Paul E., Leong, Stephanie A., Swensen, Andrine R.·2005·Current Medical Research and Opinion
DOI 10.1185/030079904x20303
Open this paper in CoChat — free account

Abstract

OBJECTIVE: The objective of this study is to provide a comprehensive estimate of the cost of ADHD by consider ing the healthcare and work loss costs of persons with ADHD, as well as those costs imposed on their family members. METHODS: Excess per capita healthcare (medical and prescription drug) and work loss (disability and work absence) costs of treated ADHD patients (ages 7 years-44 years) and their family members (under 65 years of age) were calculated using administrative claims data from a single large company; work loss costs are from disability data or imputed for medically related work loss days. Excess costs are the additional costs of patients and their family members over and above those of comparable control individuals. The excess costs of untreated individuals with ADHD and their family members were also estimated. All per capita costs were extrapolated using published prevalence and treatment rates and population data; the prevalence of persons with ADHD was based upon the literature. RESULTS: The total excess cost of ADHD in the US in 2000 was $31.6 billion. Of this total, $1.6 billion was for the ADHD treatment of patients, $12.1 billion was for all other healthcare costs of persons with ADHD, $14.2 billion was for all other healthcare costs of family members of persons with ADHD, and $3.7 billion was for the work loss cost of adults with ADHD and adult family members of persons with ADHD. CONCLUSION: The annual cost of ADHD in the US is substantial. Both treated and untreated persons with ADHD, as well as their family members, impose consider able economic burdens on the healthcare system as a result of this condition. While these first estimates of the cost of ADHD to the nation are suggestive of its substantial economic burden, future research needs to refine and build on this analysis, particularly in the context of a model to control for related co-morbidities. Similarly, since these results are based on data from a single company for the period 1996-1998, the analysis should be validated with more representative, current data.

Overview

Integrity signals

Registry

Crossref · 10.1185/030079904x20303

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 55 references

Research works printed but not linked: 11

  1. American Psychiatric Association, 2003, Fact
  2. Weiss M, 2003, Can Med Assoc J, 168, 715
  3. Barkley RA, 2002, J Clin Psychiatry, 63, 10
  4. Nechmad A, 2000, Israel J Psychiatry Rel Sci, 37, 3
  5. Kelleher KJ, 2001, Healthcare costs for children with attention-deficit/hyperactivity disorder. TEN: Trends Evidence-Based Neuropsychiatry, 3, 60
  6. Rice DP, 1985, San Francisco, CA: Institute for Health and Aging, University of California
  7. Greenberg PE, 1993, J Clin Psychiatry, 54, 405
  8. US, 2000, Washington (DC): US Bureau of the Census
  9. US, 2000, Washington (DC): US Bureau of the Census
  10. Barnett A, 2000, Am J Managed Care, 6, 1243
  11. Hodgson TA, 1999, Health Care Financ Rev, 21, 119

Cited by

Sorted by citations

Items 101–200 of 237

Related

See all

Metadata

Authors
Birnbaum, H. G., Kessler, R. C., Lowe, S. W., Secnik, K., Greenberg, P. E., Leong, S. A., & Swensen, A. R.
Affiliations
  • Analysis Group (United States) (US)
  • Harvard University (US)
  • Eli Lilly (United States) (US)
Corresponding author
Birnbaum, Howard G.
ORCID
Venue
Current Medical Research and Opinion
Publisher
Informa UK Limited
Published
2005-02
Volume
21
Issue
2
Pages
195-205
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
DOI
10.1185/030079904x20303
OpenAlex
W2111117333
Cited by
237
References
55
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 12 · 2020: 5 · 2019: 11 · 2018: 10 · 2017: 13 · 2016: 4 · 2015: 11 · 2014: 14 · 2013: 24 · 2012: 22
FWCI
9.06
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
attention deficit hyperactivity disorder, economic burden of disease, health care costs, work loss costs, relatives of patients, untreated ADHD, prescription drug costs, disability, absenteeism, economic burden
MeSH terms
Adolescent, Adult, Attention Deficit Disorder with Hyperactivity, Child, Family, Female, Humans, Male, Middle Aged, United States, Prevalence, Case-Control Studies, Health Care Costs, Cost of Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review